JP2016502522A5 - - Google Patents

Download PDF

Info

Publication number
JP2016502522A5
JP2016502522A5 JP2015542135A JP2015542135A JP2016502522A5 JP 2016502522 A5 JP2016502522 A5 JP 2016502522A5 JP 2015542135 A JP2015542135 A JP 2015542135A JP 2015542135 A JP2015542135 A JP 2015542135A JP 2016502522 A5 JP2016502522 A5 JP 2016502522A5
Authority
JP
Japan
Prior art keywords
ethyl
purin
pyrrolidin
methylpyrimidin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015542135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016502522A (ja
JP6322200B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2013/001395 external-priority patent/WO2014075393A1/en
Publication of JP2016502522A publication Critical patent/JP2016502522A/ja
Publication of JP2016502522A5 publication Critical patent/JP2016502522A5/ja
Application granted granted Critical
Publication of JP6322200B2 publication Critical patent/JP6322200B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015542135A 2012-11-16 2013-11-15 ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤 Active JP6322200B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727392P 2012-11-16 2012-11-16
US61/727,392 2012-11-16
PCT/CN2013/001395 WO2014075393A1 (en) 2012-11-16 2013-11-15 Purine inhibitors of human phosphatidylinositol 3-kinase delta

Publications (3)

Publication Number Publication Date
JP2016502522A JP2016502522A (ja) 2016-01-28
JP2016502522A5 true JP2016502522A5 (cg-RX-API-DMAC7.html) 2016-12-22
JP6322200B2 JP6322200B2 (ja) 2018-05-09

Family

ID=50730542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542135A Active JP6322200B2 (ja) 2012-11-16 2013-11-15 ヒトホスファチジルイノシトール3−キナーゼデルタのプリン阻害剤

Country Status (11)

Country Link
US (1) US9938281B2 (cg-RX-API-DMAC7.html)
EP (1) EP2920172B1 (cg-RX-API-DMAC7.html)
JP (1) JP6322200B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150084992A (cg-RX-API-DMAC7.html)
CN (1) CN104918940B (cg-RX-API-DMAC7.html)
AU (1) AU2013347539B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015011147A8 (cg-RX-API-DMAC7.html)
CA (1) CA2891013A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015006192A (cg-RX-API-DMAC7.html)
RU (1) RU2661896C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014075393A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
HRP20181367T4 (hr) 2012-11-01 2021-11-26 Infinity Pharmaceuticals, Inc. Liječenje raka korištenjem modulatora izoforme pi3 kinaze
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015178955A1 (en) * 2014-05-19 2015-11-26 Eternity Bioscience Inc. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
WO2015188369A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
KR101710127B1 (ko) * 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
WO2017000125A1 (en) * 2015-06-29 2017-01-05 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2017166104A1 (en) 2016-03-30 2017-10-05 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
CA3126224A1 (en) * 2019-01-08 2020-07-16 Phasebio Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
PT4069691T (pt) 2019-12-06 2024-12-18 Vertex Pharma Tetrahidrofuranos substituídos como moduladores dos canais de sódio
GEAP202416430A (en) 2021-06-04 2024-03-25 Vertex Pharma N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
WO2024083237A1 (en) * 2022-10-20 2024-04-25 Impact Therapeutics (Shanghai) , Inc Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof
WO2024127350A1 (en) 2022-12-16 2024-06-20 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5117830A (en) * 1990-11-08 1992-06-02 Whitby Research, Inc. Method of determining viability of tissue
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
RU2112765C1 (ru) * 1993-02-09 1998-06-10 Дзе Велкам Фаундейшн Лимитед ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ПРОЯВЛЯЮЩАЯ АКТИВНОСТЬ ПРОТИВ ВИРУСНОЙ ИНФЕКЦИИ И β D-АРАБИНОФУРАНОЗИЛ-2-АМИНО-6-МЕТОКСИ-9Н-ПУРИНЫ
US5670501A (en) * 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
EP1165545A1 (en) * 1999-03-26 2002-01-02 AstraZeneca AB Novel compounds
CA2523015A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
WO2005105803A2 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
JP4820290B2 (ja) 2004-05-13 2011-11-24 第一三共株式会社 置換ピロリジン誘導体
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MX2007010984A (es) * 2005-03-11 2008-03-18 Aderis Pharmaceuticals Inc 9-alquiladeninas sustituidas y uso de las mismas.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011075643A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
DE102010011431A1 (de) * 2009-12-23 2011-06-30 WABCO GmbH, 30453 Ventileinrichtung für eine Luftfederungsanlage
NZ601924A (en) 2010-03-10 2014-10-31 Astrazeneca Ab 4-phenyl pyridine analogues as protein kinase inhibitors
RU2012141536A (ru) 2010-03-17 2014-04-27 Ф. Хоффманн-Ля Рош Аг Имидазопиридины, композиции и способы применения
AU2011271462A1 (en) 2010-06-30 2013-01-10 Amgen Inc. Nitrogen containing heterocyclic compounds as PIK3 -delta inhibitors
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
CA2812091C (en) * 2010-09-14 2020-03-24 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
US9273028B2 (en) * 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN102838600A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂

Similar Documents

Publication Publication Date Title
JP2016502522A5 (cg-RX-API-DMAC7.html)
RU2015122894A (ru) Пуриновые ингибиторы фосфатидилинозитол-3-киназы дельта человека
JP2015537010A5 (cg-RX-API-DMAC7.html)
RU2015122895A (ru) Пуриновые ингибиторы человеческой фосфатидилинозит 3-киназы дельта
CN118955473A (zh) 通过泛素蛋白酶体途径降解btk的双官能化合物
ES2548532T3 (es) Compuestos de pirrolopirimidina como inhibidores de CDK4/6
AU2014358792C1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
AU2022209304A1 (en) Heteroaryl compounds for treating Huntington's disease
JP2024009957A (ja) アロステリックshp2阻害剤としての2,5-二置換3-メチルピラジンおよび2,5,6-三置換3-メチルピラジン
KR101735868B1 (ko) 복소고리 화합물
JP2015522002A5 (cg-RX-API-DMAC7.html)
HRP20210177T1 (hr) Supstituirani spojevi pirazolo[1,5-a]piridina kao inhibitori ret kinaze
JP2019533670A (ja) Retキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピリジン化合物
TW202132297A (zh) 經取代吡啶及使用方法
JP2015527399A5 (cg-RX-API-DMAC7.html)
CN120641428A (zh) 用于治疗自身免疫性疾病的咪唑大环
US20240109917A1 (en) Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
JP2017527628A5 (cg-RX-API-DMAC7.html)
US20250304577A1 (en) Tyk2 inhibitors
JPWO2023027518A5 (cg-RX-API-DMAC7.html)
WO2023247593A1 (en) Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
RU2023122794A (ru) Ингибиторы циклинзависимой киназы 7
CN120187719A (zh) 取代的吡啶并嘧啶酮
JPWO2020072504A5 (cg-RX-API-DMAC7.html)